Pralsetinib Patent Expiration

Pralsetinib is used for advanced or metastatic RET fusion-positive thyroid cancer and non-small cell lung cancer in certain patients. It was first introduced by Blueprint Medicines Corp in its drug Gavreto on Sep 4, 2020.


Pralsetinib Patents

Given below is the list of patents protecting Pralsetinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Gavreto US10030005 Inhibitors of RET Nov 01, 2036 Blueprint Medicines
Gavreto US11273160 RET inhibitor for use in treating cancer having a RET alteration Apr 03, 2039 Blueprint Medicines
Gavreto US11872192 RET inhibitor for use in treating cancer having a RET alteration Apr 03, 2039 Blueprint Medicines


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳